Canadian VIGOUR Centre

Coronary Reperfusion in Patients With ST-Elevation MI Requiring Transfer This Viewpoint evaluates the evolution of ST-elevation myocardial infarction guidelines on reperfusion choices and the evidence that adherence to timely reperfusion recommendations affects outcomes in...

In this @jamacardiology.com .com viewpoint, Drs. Armstrong, Bainey, & Granger advocate for aligning #STEMI time metrics with current first-point-of-contact capabilities to ensure optimized outcomes for all patients, regardless of geographic location.

jamanetwork.com/journals/jam...

Vericiguat in Heart Failure: Insights From the VICTOR Trial - American College of Cardiology

The VICTOR study results complement those of the VICTORIA by extending the evidence base for vericiguat in a contemporary lower-risk, well-treated ambulatory #HFrEF population.

Explore more insights from the VICTOR trial ➡️ https://bit.ly/4blPC0O #HeartFailure

The winter issue of the Canadian Cardiac Chronicle Newsletter is now available!

Read more about our current trials, research highlights, & other recent news & updates here: mailchi.mp/bed47c9edc60...

Now accepting applications! The CVC Scholar Program is a unique training opportunity for early-stage investigators focused on cardiovascular disease research.

Learn more & apply ➡️: thecvc.ca/programs-and...

#cardiosky #cardiology

American Society of Nephrology Kidney Week 2025 Original Article | Nov. 7, 2025 | NEJM.org Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis Fig. 1A. A Serious Cardiovascular Events The NEJM identity sits at the bottom.

In the PISCES trial involving participants receiving hemodialysis, fish oil (n−3 fatty acids) was compared with corn-oil placebo. The rate of serious cardiovascular events was lower with daily fish-oil supplementation. Full trial results: nej.md/49zWuqo

@asnkidney.bsky.social | #KidneyWk

Meet the U of A's Fall 2025 Canada Research Chairs

Congratulations to CVC Co-Director Dr. Padma Kaul, who has been named Tier 1 Canada Research Chair in Women and Children’s Cardio-Metabolic Health. 👏

www.ualberta.ca/en/the-quad/...

In STEMI patients with multivessel disease, reduced LVEF increases ischaemic risk — but the COMPLETE trial showed complete revascularisation reduces major CV events regardless of LVEF. #cardiosky #medsky #LVEF #cardiology
eurointervention.pcronline.com/article/impa...

🚨 Just published! This guideline provides multi-disciplinary clinical teams with practical recommendations for SGLT2is, MRAs, ARNI and drugs with GLP-1 receptor agonist activity.

Read the guideline here: onlinecjc.ca/article/S082...

#Cardiosky #HeartFailure

Vericiguat Improves HFrEF Regardless of Background Therapy, With Justin Ezekowitz, MD | HCPLive Ezekowitz spotlights improvement in cardiovascular mortality and heart failure hospitalization despite a failure to achieve the primary endpoint of VICTOR.

At #HFSA2025, we spoke with Justin Ezekowitz, MD, co-director of the Canadian VIGOUR Center, to discuss his analysis of background therapies in the VICTOR trial of vericiguat in HFrEF.

Watch now:

❣️The Fall 2025 issue of the CVC Chronicle newsletter is now available❣️

Read about our current trials, research highlights, & other recent news/updates here: tinyurl.com/3w4srx67

Maternal asthma a risk for babies, study shows A University of Alberta-led research team has identified an association between asthma in pregnant women and adverse outcomes for their newborns, including preterm birth, low birth weight and caesarea...

Women with asthma, particularly active asthma, are at higher risk for preterm birth, low birth weight, & C-section, highlighting the need for improved asthma monitoring & management during pregnancy. @wchriuofa.bsky.social @stollerykids.bsky.social @ualberta.bsky.social

Dr. Moorthy reviewing the WHO global action plan for clinical trial ecosystem strengthening at the 4th Annual ACT meeting in Cape Breton, NS. We are making progress in Canada but lots of work to do!
@cvcualberta.bsky.social @csnscn.bsky.social @ualberta.bsky.social

New analysis published in @jcardfail.bsky.social: applying the 5-STAR risk stratification method to VICTORIA trial data revealed a greater treatment effect for vericiguat on the composite endpoint of CV death or HF hospitalization.

Read more ➡️: authors.elsevier.com/a/1llYy3pkRz...

Happy to have had the chance to contribute to this amazing collaborative work led by @sandeepsahaymd.bsky.social and Dr Ray Benza

Figure highlighting selected opportunities for promotion of CKM health and prevention of heart failure at the individual, health-care system and community, and population and policy levels. CKM=cardiovascular-kidney-metabolic. Copyright: 2025 Elsevier Ltd. All rights reserved.

Heart failure affects more than 55 million people worldwide. 🫀

A new Lancet Series, presented at #ESC2025, serves as a call to action for clinicians, health systems, and governments to prioritise the primary prevention of heart failure. tinyurl.com/2sty9386

Late-breaking science from VICTOR & VICTORIA trials presented at #ESCCongress add to growing body of evidence surrounding vericiguat in treating patients with HFrEF. Read more: https://bit.ly/4lTUNXE
#HeartFailure

In #HFrEF, quadruple therapy (ARNi, β-blockers, MRA, #SGLT2i) improves survival. Adding #vericiguat may offer a modest ~0.7-year gain, though findings are exploratory, as they are derived from a secondary endpoint of a single trial https://bit.ly/4mE83Rp

#JACC #ESCCongress #WCCardio

The AURORA study is currently recruiting adults & adolescents with type 1 diabetes (T1D) & caregivers for an advisory group. Share your experience navigating the Alberta healthcare system & help us create a vital T1D knowledge hub!

Learn more ➡️: thecvc.ca/aurora-recru...

Priorities for lung transplantation research: a James Lind Alliance priority-setting partnership between patients, caregivers, and clinicians in Canada This study employed the James Lind Alliance Priority Setting Partnership methodology to identify and prioritize research priorities in lung transplantation through engagement of pre- and post-lung tra...

Excited to finally share our
James Lind Alliance
#Top10 Research Priorities for #LungTransplantation 🫁🔬👩🏽‍🔬

@ualberta.bsky.social
@ubcmedicine.bsky.social
@umontreal.ca @uhnresearch.ca @ucalgarymed.bsky.social

www.jhltopen.org/article/S295...

Cardiac Biomarkers Equally Apt to Rise in COVID-19, Influenza Patients who are hospitalized for either viral infection should be screened for myocardial involvement, experts say.

Patients hospitalized with influenza are just as likely as COVID-19 patients to have signs of myocardial involvement. Lead study author Finlay McAlister said the findings show a need to screen and monitor patients more closely. www.tctmd.com/news/cardiac...

New in @jaccjournals.bsky.social: A secondary analysis of the VICTORIA trial investigates the impact of geographic variation and Human Development Index on heart failure outcomes. 🫀 🌏

Read more here: www.sciencedirect.com/science/arti...

💭 Review of transcatheter aortic valve insertion (#TAVI) clinician opinions on the CCS Post-TAVI Driving Guidelines: is a 1-month driving restriction period overly cautious? Read more ⬇️
cjcopen.ca/article/S258...
#CJCO #OpenAccess

Among patients with opioid-associated out-of-hospital cardiac arrest, chest compression and ventilation CPR was associated with a higher odds of favorable neurologic outcomes at hospital discharge.

ja.ma/4l7We4q

I’m Aware That I’m Rare: Jason Weatherald, MD (524) the phaware® interview

Dr. Jason Weatherald explains how your everyday clinic visits can help shape the future of pulmonary hypertension treatment. @phaware.bsky.social podcast ep 524 @phacanada #phawareMD @teamphhope @albertaphdoc.bsky.social @ualberta.bsky.social medium.com/p/im-aware-t...

🫀 Join us June 11 for our webinar: Heart-Healthy Eating: Evidence-Based Nutrition for Cardiovascular Health!

🔗 Register now! ow.ly/yBOO50W5aZP

#cardiosky

UCalgary experts investigate effects of climate change on child health, and possible solutions Transdisciplinary project one of six research programs announced by One Child Every Child initiative

Dr. Padma Kaul will lead a #OneChildEveryChild program exploring how clinical, genetic, socio-economic, & behavioral factors impact neonatal & early childhood outcomes following pregnancy complications. @wchriuofa.bsky.social

Read more about the OCEC initiative ⬇️

www.ucalgary.ca/news/ucalgar...

❣️The Spring 2025 issue of the CVC Chronicle newsletter is now available ❣️

Read about our current trials, research highlights, & other recent news/updates here: mailchi.mp/3fed258d1c05...

New research: Women with asthma, particularly active asthma, are at higher risk for preterm birth, low birth weight, & C-section. These findings highlight the need for improved asthma monitoring & management during pregnancy. @wchriuofa.bsky.social

Read here: www.sciencedirect.com/science/arti...

Featured CJC Open article from CVC authors highlights the substantial and likely rising cost of heart failure hospitalizations in Canada, underscoring the urgent need for strategic solutions.

Read here ▶️: www.cjcopen.ca/article/S258...

#HeartFailureWeekCan

Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism Nature Reviews Cardiology, Published online: 31 March 2025; doi:10.1038/s41569-025-01144-zInhibition of factor XI has emerged as a promising strategy to mitigate bleeding while potentially preserving antithrombotic efficacy. In this Review, the authors comprehensively discuss the rationale, pharmacology, evidence and future directions for factor XI inhibitors across various clinical settings.

New online! Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism #CardioSky